Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;13(4):221-6.

Lack of association of DRD3 and CNR1 polymorphisms with premenstrual dysphoric disorders

Mesut Yıldız  1 , Mehmet Vural  2 , Mehmet Emin Erdal  3 , Özlem İzci Ay  3 , Şenay Görücü Yılmaz  3 , İbrahim Fatih Karababa  4 , Salih Selek  5
Affiliations

Lack of association of DRD3 and CNR1 polymorphisms with premenstrual dysphoric disorders

Mesut Yıldız et al. Iran J Reprod Med. 2015 Apr.

Abstract

Background: Premenstrual dysphoric disorder (PMDD) is a mood disorder characterized with physical and affective symptoms during the luteal phase of susceptible women.

Objective: The aim of this study was to investigate the association of Dopamine D3 receptor (DRD3) polymorphism, and Cannabinoid receptor Type 1 (CNR1) polymorphism with PMDD.

Materials and methods: Fifty one participants with documented PMDD according to the DSM IV criteria and 51 healthy controls were included in this cross sectional study. Symptom severity was measured with daily self-rating, monthly premenstrual assessment forms and psychiatric interviews. The genotyping of DRD3 receptor and Cannabinoid type 1 receptors were performed using Taqmanfluorogenic assay method.

Results: Distribution of DRD3 and CNR1 polymorphism was not different between patients and controls.

Conclusion: These findings do not support a major role of DRD3, and CNR1 polymorphisms in contributing to susceptibility to premenstrual dysphoric disorder.

Keywords: Cannabinoid receptor; Dopamine D3 receptor; Genetic polymorphism; Premenstrual syndrome.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand . 2001;104:110–116. - PubMed
    1. American Psychiatric Association, statistical manual of mental disorders: DSM IV. Diagnostic and statistical manual of mental disorders: DSM IV. 4th Ed. Washington (DC): American Psychiatric Publishing; 1994.
    1. Henshaw CA. PMS: diagnosis, aetiology, assessment and management Revisiting Premenstrual syndrome. Adv PsychiatrTreatment . 2007;13:139–146.
    1. Halbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndrome. Int J Psychiatry Med. 1993;23:1–27. - PubMed
    1. Parry BL. The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications. CNS Drugs. 2001;15:277–285. - PubMed

LinkOut - more resources